Breast Cancer Treatment Options: Surgery, Radiation, and Beyond

For many women, a breast cancer diagnosis feels overwhelming, not just because of the disease but because of how complex the treatment process appears at first. That complexity, however, reflects progress.

Modern breast cancer treatment is not one-size-fits-all. It is structured, evidence-based, and increasingly personalized, built around tumor biology, stage, and individual patient factors.

This article breaks down that process. It explains the main treatment options, how they work together, and what actually determines which therapies are recommended. The goal is to make the structure behind treatment decisions clearer, so patients can move from confusion to informed participation in their care.

Read More: Empowerment and Education: Understanding Breast Cancer

How Breast Cancer Treatment Plans Are Decided

No two breast cancer cases are identical, and the treatment planning process reflects that. Several factors shape which therapies are recommended, in what order, and at what intensity. Stage determines how far the cancer has spread and guides the overall treatment framework.

Early-stage breast cancer treatment, where the tumor is small and confined to the breast, typically involves fewer and less intensive interventions than locally advanced or metastatic disease. Tumor size influences surgical options directly and affects decisions about chemotherapy. Receptor testing is among the most consequential steps in treatment planning.

An estrogen receptor-positive tumor responds to hormones and is typically treated with hormone therapy. A HER2-positive breast cancer overexpresses a growth-promoting protein that can be targeted by specific drugs.

Triple-negative breast cancer, which lacks all three markers, is treated differently. This biology-first approach defines what systemic therapies will actually work for each patient. Whether cancer has reached the lymph nodes changes both the staging and the recommendation for systemic therapy.

Positive nodes often expand the indication for chemotherapy and may influence the extent of radiation therapy delivered. A patient’s age, overall health, prior diagnoses, fertility goals, and personal values all shape which options are realistic and appropriate.

Shared decision-making is central to good breast cancer care, and patients are active participants in building their breast cancer treatment plan. That principle of individualization extends across every specialty involved in breast cancer care.

The multidisciplinary cancer care team typically includes a surgical oncologist, a medical oncologist, and a radiation oncologist, often coordinating alongside pathologists, radiologists, genetic counselors, and nurse navigators. Each specialist brings a different lens to the same case.

Surgery: Removing the Cancer

Surgery is the primary local treatment for most breast cancers. The goal is to remove the tumor with clear margins, meaning no cancer cells at the edge of what was removed, while preserving as much healthy tissue as quality of care allows.

Lumpectomy (Breast-Conserving Surgery)

A lumpectomy removes the tumor and a small margin of surrounding tissue while leaving the breast largely intact. It is typically followed by radiation therapy to address any microscopic cancer cells that may remain in the breast tissue.

Lumpectomy is appropriate for many women with early-stage breast cancer, particularly when the tumor is small relative to breast size, when the cancer is localized, and when the patient can receive radiation afterward.

A landmark 20-year follow-up study published in the New England Journal of Medicine confirmed that lumpectomy followed by radiation produces overall survival rates that are not significantly different from those achieved with total mastectomy in eligible patients, supporting breast conservation as a medically equivalent option in appropriate cases.

Recovery from lumpectomy is generally faster than from mastectomy. Most women return to normal activities within two to three weeks.

Mastectomy

A mastectomy removes the entire breast. Several variants exist: a simple (total) mastectomy removes only breast tissue; a modified radical mastectomy removes breast tissue along with some lymph nodes; a skin-sparing mastectomy preserves the skin envelope for reconstruction purposes; and a nipple-sparing mastectomy preserves both skin and nipple when oncologically safe.

Mastectomy may be considered when the tumor is large relative to breast size, when multiple tumors are present in different parts of the breast, when a patient carries a BRCA1 or BRCA2 gene mutation that significantly elevates future cancer risk, or when a patient simply prefers complete removal.

Breast reconstruction, either immediate or delayed, is a well-established option following mastectomy and should be discussed before surgery whenever possible.

A 2024 study published in JAMA Oncology examining over 100,000 women over 20 years of follow-up found that lumpectomy, unilateral mastectomy, and bilateral mastectomy produced statistically similar rates of breast cancer mortality, reinforcing that the choice between lumpectomy vs. mastectomy for eligible patients is often driven by personal preference, genetic risk, and tumor characteristics rather than survival benefit alone.

Lymph Node Surgery

Lymph node evaluation is a standard part of breast cancer surgery. The sentinel lymph node biopsy removes the one to three lymph nodes most likely to receive drainage from the tumor site. If those nodes are cancer-free, the remaining nodes are typically left in place.

Axillary lymph node dissection, which removes a larger number of nodes, is reserved for cases where sentinel nodes contain cancer or where more extensive evaluation is needed. Lymph node status directly informs staging and systemic therapy recommendations.

Radiation Therapy: Targeting Remaining Cancer Cells

Radiation therapy uses focused high-energy beams to destroy cancer cells that may remain after surgery. It is a local treatment and plays a key role in reducing the risk of recurrence. External beam radiation is the most common type, delivered from outside the body.

Techniques like IMRT and breath-hold methods improve precision and help protect nearby organs such as the heart and lungs. Radiation is typically recommended after lumpectomy and may be used after mastectomy in higher-risk cases, such as larger tumors or lymph node involvement.

Decisions about omitting radiation depend on individual risk. Treatment is usually given over 3 to 7 weeks. Short-term effects include fatigue and skin changes, while long-term risks are minimized with modern techniques.

Chemotherapy: Treating Cancer Throughout the Body

Chemotherapy uses drugs that circulate through the body to destroy cancer cells or stop them from dividing. Unlike surgery or radiation, it is systemic and can target cancer that may have spread beyond the breast.

Not all breast cancers require chemotherapy. It is most often used for triple-negative and HER2-positive cancers, larger or more aggressive tumors, and when lymph nodes are involved. Genomic tests like Oncotype DX can help determine whether chemotherapy will provide meaningful benefit in certain early-stage cases.

Adjuvant chemotherapy is given after surgery to reduce recurrence risk, while neoadjuvant chemotherapy is given before surgery to shrink tumors and assess response. It is commonly used in HER2-positive and triple-negative cancers.

Chemotherapy is typically given intravenously in cycles with rest periods. Side effects may include fatigue, nausea, hair loss, and infection risk, though supportive care has improved tolerability.

Hormone Therapy for Hormone Receptor-Positive Breast Cancer

Hormone therapy for breast cancer, also called endocrine therapy, works by reducing or blocking the estrogen that fuels estrogen receptor-positive tumors. It is one of the most effective treatments available for this subtype and is used in both early-stage and metastatic settings.

How It Works and Who Benefits Most

Tamoxifen blocks estrogen receptors in breast tissue and is used in premenopausal women as well as some postmenopausal women. Aromatase inhibitors, including anastrozole, letrozole, and exemestane, reduce estrogen production and are the preferred option in postmenopausal women.

CDK4/6 inhibitors, including palbociclib, ribociclib, and abemaciclib, are a newer class often added to endocrine therapy in advanced hormone receptor-positive, HER2-negative disease.

Dr. Harold J. Burstein, MD, PhD, FASCO, Professor of Medicine at Harvard Medical School and a medical oncologist in the Breast Oncology Center at Dana-Farber Cancer Institute, has described CDK4/6 inhibitors as having fundamentally changed the treatment landscape.

Discussing real-world data on palbociclib with The ASCO Post, he stated that “the benefits of palbociclib are as substantial as seen in the clinical trial,” calling it a “valuable real-world confirmation of what has become our standard practice” for women with advanced breast cancer.

Duration of Treatment

Standard adjuvant hormone therapy runs for five years, and evidence supports extending it to ten years for higher-risk patients to further reduce recurrence. Duration decisions are individualized based on recurrence risk, side effect profile, and patient tolerance.

Targeted Therapy: Precision Treatment Based on Tumor Biology

Targeted therapy differs from chemotherapy by focusing on specific molecular pathways that cancer cells depend on, rather than broadly attacking all dividing cells. In HER2-positive breast cancer, drugs like trastuzumab (Herceptin) form the foundation of treatment, often combined with pertuzumab in higher-risk cases.

Advanced options such as T-DM1 and T-DXd deliver treatment directly to HER2-positive cells and are used in more specific settings, including residual or metastatic disease. While targeted therapies tend to have a more favorable side-effect profile, they still require monitoring, particularly for cardiac effects. Their use depends on cancer stage, prior treatment, and HER2 expression levels.

Immunotherapy in Selected Cases

Immunotherapy works by helping the immune system recognize and attack cancer cells. In breast cancer, its current role is most established in triple-negative breast cancer.

Pembrolizumab, an immune checkpoint inhibitor, is approved in combination with chemotherapy as neoadjuvant therapy for early-stage, high-risk triple-negative breast cancer and continued as monotherapy in the adjuvant setting following surgery.

A pivotal trial published in the New England Journal of Medicine demonstrated that adding pembrolizumab to neoadjuvant chemotherapy significantly improved pathologic complete response rates in high-risk, early-stage triple-negative breast cancer.

Immunotherapy is not routinely used for hormone receptor-positive or HER2-positive breast cancer, though research into its role in these subtypes is ongoing. Side effects can include immune-related inflammation affecting the lungs, liver, and other organs, and careful monitoring is required.

Additional Treatment Considerations

Bisphosphonates such as zoledronic acid and denosumab reduce bone loss caused by cancer treatment and, in postmenopausal women, have shown a modest benefit in reducing the risk of bone metastases. They are frequently incorporated into adjuvant treatment plans.

For premenopausal women with hormone receptor-positive breast cancer, adding ovarian suppression (with medications such as goserelin or leuprolide) to aromatase inhibitor therapy has been shown to further reduce recurrence risk in higher-risk patients compared to tamoxifen alone.

Clinical trials offer access to emerging treatments that are not yet broadly available. Patients should ask their oncologist whether a trial is appropriate at any point in their treatment course. Major cancer centers routinely offer trial enrollment and can help patients identify relevant options.

Supportive care, including anti-nausea medications, growth factors to support white blood cell counts, pain management, nutritional guidance, and mental health support, is not an afterthought. It is a clinically important component of keeping patients safe, comfortable, and able to complete their planned therapy.

Possible Side Effects and How They Are Managed

Short-term treatment effects are common and manageable. Fatigue, nausea, hair loss (with some chemotherapy regimens), skin changes from radiation, and hot flashes from hormone therapy are among the most frequently reported. Each has corresponding supportive strategies.

Long-term considerations vary by treatment type. Hormone therapy can contribute to bone density loss, joint pain, and menopausal symptoms. Certain chemotherapy agents carry a small risk of long-term cardiac effects or neuropathy. Regular monitoring during and after treatment allows the care team to identify and address these issues early.

Ongoing communication with the care team is the most effective tool a patient has. Side effects that are disclosed can be managed. Those that go unreported cannot.

What to Expect During Treatment Planning

After a breast cancer diagnosis is confirmed, the staging workup typically includes additional imaging (such as CT scans, bone scans, or PET scans for higher-stage disease), pathology review, and receptor testing. This process usually takes one to two weeks before treatment planning is finalized.

Therapies are often given in sequence: surgery first, followed by chemotherapy and radiation, then long-term hormone therapy. In some cases, neoadjuvant chemotherapy precedes surgery. Follow-up appointments continue throughout and after active treatment, with mammograms and clinical exams at defined intervals depending on the patient’s history and risk profile.

Treatment plans can and do change. If a tumor does not respond as expected to neoadjuvant therapy or if a side effect becomes intolerable, adjustments are made. Flexibility is built into modern breast cancer care.

Questions to Ask Your Care Team

Understanding your own treatment requires asking specific questions. What is the goal of each recommended therapy? What are the short and long-term risks? What happens if this treatment does not work? How will this affect fertility? What is the plan for managing menopause symptoms if treatment triggers them? Are there clinical trials I should consider?

Patients who ask detailed questions are better equipped to participate in decisions that reflect their values.

When to Seek Additional Support

A breast cancer diagnosis affects every area of a person’s life. Emotional support, whether through a therapist, a peer support group, or a social worker embedded in the cancer center, is not a luxury. It is part of comprehensive cancer care and has been shown to improve quality of life and, in some research, treatment adherence.

Registered dietitians with oncology expertise can guide nutrition strategies during treatment, particularly for managing nausea, maintaining weight, and supporting immune function. Physical activity, adapted to each patient’s capacity, has demonstrated benefits for fatigue, mood, and even recurrence risk in some populations.

Survivorship planning should begin before treatment ends, not after. It includes monitoring for late effects, managing ongoing medication, and maintaining a clear record of which treatments were received and when.

Read More: Breast Health Essentials: 7 Products for Breast Care and Comfort

Practical Takeaway: Treatment Is Personalized and Often Combined

Breast cancer treatment options are not a menu to choose from. They are components of a coordinated plan designed around a specific cancer in a specific person at a specific point in time. Surgery addresses the local tumor. Radiation reduces local recurrence.

Chemotherapy, hormone therapy, and targeted therapy address systemic risk based on the biology of the cancer. Immunotherapy plays an emerging and increasingly defined role in specific subtypes. That translation is happening constantly, which means how breast cancer is treated today looks meaningfully different from how it was treated even five years ago.

The most important thing a newly diagnosed patient can do is build a relationship with a multidisciplinary team that explains each decision clearly, incorporates her values into the plan, and remains responsive as circumstances evolve. Good treatment is not just technically precise. It is also genuinely collaborative.